Drugs / MBF-362
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05940571 | Nov 2022 → Nov 2024 | cancer | Medibiofarma S.L. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-22 | Medibiofarma S.L. | Medibiofarma announces the first subject dosed in the Phase I clinical trial of MBF-362 in cancer patients with solid tumours. medibiofarma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBF-362 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05940571 ↗ |
| Action | Inhibit | “EP2/EP4 antagonist” NCT05940571 ↗ |
| Route | Oral | “single oral daily dosing cycles” NCT05940571 ↗ |